Fibrin Sealant Grifols + EVICEL
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Excessive Bleeding During Surgery
Conditions
Excessive Bleeding During Surgery
Trial Timeline
Jan 18, 2019 → May 20, 2022
NCT ID
NCT03461406About Fibrin Sealant Grifols + EVICEL
Fibrin Sealant Grifols + EVICEL is a phase 3 stage product being developed by Grifols for Excessive Bleeding During Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT03461406. Target conditions include Excessive Bleeding During Surgery.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03461406 | Phase 3 | Completed |
Competing Products
8 competing products in Excessive Bleeding During Surgery
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + PF-03654746 | Pfizer | Phase 2 | 51 |
| JZP-110 | Jazz Pharmaceuticals | Phase 2 | 49 |
| Solriamfetol + Placebo | Axsome Therapeutics | Approved | 82 |
| Solriamfetol 150 MG + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol Oral Tablet + Placebo | Axsome Therapeutics | Approved | 82 |
| ORX142 Tablets | Centessa Pharmaceuticals | Phase 1 | 28 |
| VSF-173 | Vanda Pharmaceuticals | Phase 2 | 44 |